Evidence map›Paper›PMID 37322174›Full record

ReviewNature reviews. Immunology2023

The multifunctional protein HMGB1: 50 years of discovery.

Daolin Tang, Rui Kang, Herbert J Zeh, Michael T Lotze

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 217 papers.

0numbers the graph read from it
0cells of the map it votes in
217citing papers in PubMed
57.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

217 citing papers in PubMed, 303 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. NINJ1: implications for plasma membrane rupture and disease.Biochemical Society transactions · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. HMGB1 as a danger signal in vascular remodeling.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026
    Review
  10. Article
  11. Review
  12. Structural and molecular principles of DAMP biology.Nature structural & molecular biology · 2026
    Review
  13. Review
  14. The role of HMGB1 in vascular endothelial cells.Apoptosis : an international journal on programmed cell death · 2026
    Review
  15. Are Sputum High Mobility Group Box 1 and D-Dimer Changes Relevant Markers of Tissue Damage and Fibrinolysis in Cystic Fibrosis?Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Article
  16. A preliminary study of HMGB1 defense in Crohn's disease.bioRxiv : the preprint server for biology · 2026
    Article
  17. Article
  18. Revealing the Biological Effect of theJournal of the American Chemical Society · 2026
    Article
  19. Article
  20. Article

157 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Daolin TangDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX, USA. daolin.tang@utsouthwestern.edu.ORCID 0000-0002-1903-6180
Rui KangDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX, USA.
Herbert J ZehDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX, USA.
Michael T LotzeDepartments of Surgery, Immunology and Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA. lotzemt@upmc.edu.ORCID 0000-0003-3988-5419
Southwestern Medical Center · USUniversity of Pittsburgh · US

Funding

Targeting HMGB1-mediated Autophagy in Cancer TherapyR01CA160417 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI TANG, DAOLIN · 2012 to 2023
$3.0M
Mechanisms of Ferroptotic Cancer Cell DeathR01CA229275 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI TANG, DAOLIN · 2019 to 2024
$1.8M
The Pancreatic Cancer MicroenvironmentR01CA211070 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI KANG, RUI · 2017 to 2023
$1.4M
NCI NIH HHS R01 CA160417NCI NIH HHS R01 CA211070NCI NIH HHS R01 CA229275
6 · The paper itself

Abstract

Fifty years since the initial discovery of HMGB1 in 1973 as a structural protein of chromatin, HMGB1 is now known to regulate diverse biological processes depending on its subcellular or extracellular localization. These functions include promoting DNA damage repair in the nucleus, sensing nucleic acids and inducing innate immune responses and autophagy in the cytosol and binding protein partners in the extracellular environment and stimulating immunoreceptors. In addition, HMGB1 is a broad sensor of cellular stress that balances cell death and survival responses essential for cellular homeostasis and tissue maintenance. HMGB1 is also an important mediator secreted by immune cells that is involved in a range of pathological conditions, including infectious diseases, ischaemia-reperfusion injury, autoimmunity, cardiovascular and neurodegenerative diseases, metabolic disorders and cancer. In this Review, we discuss the signalling mechanisms, cellular functions and clinical relevance of HMGB1 and describe strategies to modify its release and biological activities in the setting of various diseases.

Indexed as

HMGB1 ProteinNeoplasmsCell DeathHumansImmunity, InnateSignal TransductionHMGB1 Protein

Identifiers

PMID37322174
OpenAlexW4380792003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.